NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

NCT04470947

UnknownN/A

Sponsor: Medical University of Vienna

Conditions: Advanced Lymphoma, Refractory Lymphoma, Refractory Leukemia, Refractory Acute Myeloid Leukemia, Refractory T-Cell Lymphoma

Interventions: Next generation functional drug screening, Comprehensive genomic profiling

Countries: Austria

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies.
* duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment.
* best response to previous treatment has to be available.
* The patient is able to give written informed consent and wishes to undergo further therapy
* further therapy is medically feasible
* tumor cell-containing samples can be obtained

Exclusion Criteria:

* current participation in another experimental clinical trial
* performance status does not allow participation (ECOG ˃ 1)
* pregnancy, tested at screening
* patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma.
* other malignoma, diagnosed \<1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)

Locations (1)

Vienna, Austria